PMC8288029_01
On December 17, 2020, the whole abdominal enhanced CT in our hospital showed a large number of peritoneal effusion, multiple metastases of omentum and mesentery (A, B), liver II metastases (C, red arrow) and V metastases (D, yellow arrow).
fonc-11-688231-g001.jpg
PMC8288029_01_fonc-11-688231-g001.jpg
f1
On December 17, 2020, the whole abdominal enhanced CT in our hospital showed liver II and V metastases considered, a large number of peritoneal effusion, and multiple metastases of omentum and mesentery ( Figure 1 ).
(A, B) The severe rashes after receiving fruquintinib for approximately 2 weeks.
fonc-11-688231-g002.jpg
PMC8288029_01_fonc-11-688231-g002.jpg
f2
On January 12, 2021, the patient developed severe rashes after receiving fruquintinib (3 mg qd) for approximately 2 weeks ( Figures 2A, B ).
The case timeline.
fonc-11-688231-g003.jpg
PMC8288029_01_fonc-11-688231-g003.jpg
f3
The case timeline is presented in  Figure 3 .